Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels

Plain-language summary

This study evaluates the effect of long-term treatment with Gecacitinib on myelofibrosis and on gene-mutation levels. It enrolls patients who previously took part in Gecacitinib clinical trials for myelofibrosis and are still receiving this treatment. It is a study with no assigned phase and is not currently recruiting but is still ongoing.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Active, not recruiting

Sponsor

First Affiliated Hospital of Zhejiang University

Start date

8/1/2025

Estimated completion

12/7/2027

Countries

China

Related genes

Locations

• Hangzhou, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* They had been enrolled in previous clinical trials of gefitinib for myelofibrosis (ZGJAK002, ZGJAK006, ZGJAK016 and ZGJAK017) and were still receiving gefitinib treatment.
* Comply with the requirements of the ethics committee, voluntarily sign the informed consent.
* Able to adhere to study and follow-up procedures.

Exclusion Criteria:

* Patients with other serious diseases that the researcher believes may affect patient compliance and outcome observation.